tesaglitazar has been researched along with rosiglitazone in 20 studies
| Studies (tesaglitazar) | Trials (tesaglitazar) | Recent Studies (post-2010) (tesaglitazar) | Studies (rosiglitazone) | Trials (rosiglitazone) | Recent Studies (post-2010) (rosiglitazone) |
|---|---|---|---|---|---|
| 74 | 13 | 25 | 4,749 | 556 | 1,818 |
| Protein | Taxonomy | tesaglitazar (IC50) | rosiglitazone (IC50) |
|---|---|---|---|
| CDGSH iron-sulfur domain-containing protein 1 | Rattus norvegicus (Norway rat) | 1.1 | |
| Bile salt export pump | Homo sapiens (human) | 4.5853 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.069 | |
| Peroxisome proliferator-activated receptor alpha | Mus musculus (house mouse) | 0.08 | |
| Thromboxane-A synthase | Homo sapiens (human) | 3.56 | |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | 0.832 | |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.2481 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.038 | |
| ATP-binding cassette sub-family C member 8 | Homo sapiens (human) | 0.048 | |
| ATP-sensitive inward rectifier potassium channel 11 | Homo sapiens (human) | 0.048 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 5.1 | |
| CDGSH iron-sulfur domain-containing protein 2 | Homo sapiens (human) | 2.29 | |
| CDGSH iron-sulfur domain-containing protein 1 | Homo sapiens (human) | 0.731 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (65.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deussen, HJ; Ebdrup, S; Fleckner, J; Frost Jensen, A; Mortensen, SB; Nygaard, L; Pettersson, I; Pridal, L; Rasmussen, HB; Sauerberg, P | 1 |
| Henke, BR | 1 |
| Chung, HK; Dong Koo, K; Ho Woo, S; Hur, GC; Joo Yim, H; Kim, GT; Kim, KH; Kim, SH; Lee, CS; Oon Han, H; Sung Koh, J | 1 |
| Chander, R; Chaturvedi, D; Ray, S; Srivastava, AK | 1 |
| Audinot-Bouchez, V; Boutin, JA; Caignard, DH; Dacquet, C; Guillard, J; Hennuyer, N; Ktorza, A; Parmenon, C; Staels, B; Viaud-Massuard, MC | 2 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Giri, S; Goel, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Pingali, H; Shah, S; Zaware, P | 1 |
| Ahn, BN; Bae, MH; Chong, W; Han, T; Kim, E; Kim, EJ; Kim, JK; Kim, MK; Kim, SH; Lee, CH; Lim, JI; Moon, HS; Park, CS; Shim, HJ; Shin, CY; Shin, YA; Son, MH | 1 |
| Basu, S; Giri, S; Godha, A; Goel, A; Goswami, A; Jain, M; Makadia, P; Patel, H; Patel, M; Patel, P; Patil, P; Pingali, H; Shah, S; Zaware, P | 1 |
| Chae, YN; Chang, DJ; Jung, JW; Kang, HJ; Kim, MK; Kim, NJ; Koo, BW; Le, TV; Lee, KO; Li, F; Lim, JI; Moon, SH; Paek, SM; Park, HJ; Ryu, JS; Shin, CY; Shin, DH; Suh, YG | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bahekar, R; Giri, S; Jain, M; Makadia, P; Patel, D; Patel, P; Pingali, H; Pola, S; Priyadarshini, P; Shah, M; Shah, SR; Suthar, D; Thube, B; Trivedi, C; Zaware, P | 1 |
| Basu, S; Giri, S; Gite, A; Godha, A; Goswami, A; Jain, M; Patel, P; Pingali, H; Raval, P; Raval, S; Shah, M; Suthar, D | 1 |
| Kagechika, K; Kubo, H; Shibata, Y; Usui, H; Yamaguchi, M | 1 |
| Hashimoto, Y; Ishikawa, M; Makishima, M; Noguchi-Yachide, T; Okazaki, S; Shioi, R; Yamaguchi, T | 1 |
| Amaudrut, J; Barth, M; Binet, J; Boubia, B; Broqua, P; Chatar, M; Dodey, P; Ferry, S; Gauthier, E; Guillier, F; Jacquier, E; Junien, JL; Lacombe, O; Legendre, C; Lepais, V; Llacer, J; Luccarini, JM; Masson, P; Montalbetti, C; Mounier, L; Peralba, P; Poupardin, O; Thourigny, A; Wettstein, G | 1 |
| Kaya, T; Sheu, SH; Vajda, S; Waxman, DJ | 1 |
| Claude, N; Guillouzo, A; Renaud, MP; Rogue, A; Spire, C | 1 |
1 review(s) available for tesaglitazar and rosiglitazone
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
19 other study(ies) available for tesaglitazar and rosiglitazone
| Article | Year |
|---|---|
Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
Topics: Binding Sites; Crystallography, X-Ray; Hypoglycemic Agents; Ligands; Models, Molecular; Oxazines; Phenylpropionates; Radioligand Assay; Receptors, Cytoplasmic and Nuclear; Stereoisomerism; Transcription Factors | 2003 |
Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.
Topics: Animals; Area Under Curve; Biological Availability; Blood Glucose; Cell Line, Tumor; Drug Design; Humans; Hypoglycemic Agents; Indicators and Reagents; Lipids; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Models, Molecular; Phenylpropionates; PPAR alpha; PPAR gamma; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Triglycerides | 2007 |
Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
Topics: Alkanes; Alkylation; Amination; Animals; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Male; Molecular Structure; Naphthalenes; PPAR gamma; Rats; Structure-Activity Relationship | 2008 |
4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.
Topics: Hypoglycemic Agents; Molecular Structure; PPAR alpha; PPAR gamma; Quinolines; Structure-Activity Relationship | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
Topics: Animals; Carboxylic Acids; Diabetes Mellitus; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred NOD; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Zucker; Structure-Activity Relationship | 2008 |
Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.
Topics: Animals; Combinatorial Chemistry Techniques; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Design; Mice; Molecular Structure; PPAR alpha; PPAR gamma; Pyridines; Rats; Rats, Sprague-Dawley | 2008 |
Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.
Topics: Animals; Carboxylic Acids; Diabetes Mellitus, Type 2; Dioxanes; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Mesylates; Mice; Models, Chemical; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Transcriptional Activation | 2008 |
Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
Topics: Animals; Cell Line; Drug Design; Humans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Phenylpropionates; PPAR alpha; PPAR gamma; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation | 2008 |
4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
Topics: Animals; Cell Line; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Mice; Oximes; PPAR alpha; PPAR gamma; Quinolines; Rats; Structure-Activity Relationship | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.
Topics: Animals; Cricetinae; Disease Models, Animal; Ether; Hep G2 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Obese; Oximes; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Structure-Activity Relationship; Thiazoles | 2011 |
Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
Topics: Administration, Oral; Animals; Cell Line; Dose-Response Relationship, Drug; Hypoglycemic Agents; Inhibitory Concentration 50; Mice; Molecular Structure; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Binding; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Thiophenes | 2011 |
Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1).
Topics: Animals; Blood Glucose; Drug Design; Mice; PPAR alpha; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones; Triglycerides; Weight Gain | 2012 |
Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor α/δ (PPARα/δ) dual agonists.
Topics: Acetamides; Binding Sites; Genes, Reporter; HEK293 Cells; Humans; Ligands; PPAR alpha; PPAR delta; Protein Binding; Stereoisomerism; Thiazolidinediones | 2017 |
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Topics: Animals; Benzothiazoles; Carbon Tetrachloride Poisoning; Cell Line; Drug Discovery; Fibrosis; Hepatocytes; High-Throughput Screening Assays; Humans; Hypoglycemic Agents; Indoles; Mice; Mice, Inbred C57BL; Models, Molecular; Molecular Structure; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Sulfonamides | 2018 |
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
Topics: Alkanesulfonates; Binding Sites; Cinnamates; Computational Biology; Humans; Ligands; Oxazines; Oxazoles; Phenylpropionates; PPAR gamma; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Rosiglitazone; Solvents; Thiazoles; Thiazolidinediones; Thiazolidines; Tyrosine | 2005 |
Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Topics: Alkanesulfonates; Animals; Chromans; Gene Expression Profiling; Genes; Glycine; Hepatocytes; Humans; Male; Oligonucleotide Array Sequence Analysis; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |